Last reviewed · How we verify
ketamine venlafaxine
Ketamine is an NMDA receptor antagonist, while venlafaxine is a serotonin-norepinephrine reuptake inhibitor.
Ketamine is an NMDA receptor antagonist, while venlafaxine is a serotonin-norepinephrine reuptake inhibitor. Used for Treatment-resistant depression, Major depressive disorder.
At a glance
| Generic name | ketamine venlafaxine |
|---|---|
| Sponsor | University Hospital, Grenoble |
| Drug class | NMDA receptor antagonist, SNRI |
| Target | NMDA receptor, SERT, NET |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
Ketamine's mechanism of action involves blocking the NMDA receptor, which is involved in the regulation of synaptic plasticity and memory formation. Venlafaxine, on the other hand, works by inhibiting the reuptake of serotonin and norepinephrine, increasing their levels in the synaptic cleft and enhancing neurotransmission.
Approved indications
- Treatment-resistant depression
- Major depressive disorder
Common side effects
- Dizziness
- Nausea
- Headache
- Increased heart rate
- Increased blood pressure
Key clinical trials
- The Efficacy and Safety of Short Term S-ketamine Infusion as an Adjunctive Therapy in Patients With Fibromyalgia (NA)
- Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure (PHASE3)
- Early Effects of Ketamine vs Placebo With Venlafaxine in Severe Depression Patients (PHASE3)
- A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression (PHASE3)
- A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression (PHASE3)
- A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression (PHASE3)
- A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression (PHASE3)
- A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ketamine venlafaxine CI brief — competitive landscape report
- ketamine venlafaxine updates RSS · CI watch RSS
- University Hospital, Grenoble portfolio CI